Top Tweets for #PATHJC

about 5 years ago

@path_JC @AnneMillsMD @UVA_Pathology Thank you @path_JC @AnneMillsMD @PAPatilMD for all the insights!! Amazing articles for discussion!! Till next time! #pathJC

1

3

2

0

about 5 years ago

#PathJC Time to wrap up our #PathJC today at 9:30 pm EST, until we meet next time ! Thank you everyone for joining the discussion! A big thanks to our guest expert @AnneMillsMD of @UVA_Pathology for joining us today !

1

4

3

0

about 5 years ago

@path_JC I hope future research might uncover if MHC class I loss can be an additional predictive marker for effectiveness of immunotherapies targetting PD-L1. It already seems a sound premise in theory. 🤔 #pathJC

0

2

0

about 5 years ago

Exactly! Future studies on these should be done in tandem with our oncologist colleagues, so much to explore with the molecular landscape of tumors being more and more familiar! All for better outcomes for our patients 🙏🏼#pathJC

Pallavi A. Patil, MD @PAPatilMD

about 5 years ago

#PathJC Study limitations -MHC class I expression was evaluated on a single tumor section - Future studies of MHC class I expression among immunotherapy responders and non-responders will be critical

0

2

0

3

2

0

about 5 years ago

#pathjc was MHC class I expression loss on macrophages/immune cells found incidentally? (on the lines of PD-L1 CPS score that includes immune cells) A study reported MHC-I-restricted antigen presentation by macrophages was inhibited by Tim-3 PMID: 31586389

0

1

0

about 5 years ago

#PathJC Study limitations -MHC class I expression was evaluated on a single tumor section - Future studies of MHC class I expression among immunotherapy responders and non-responders will be critical

0

2

0

about 5 years ago

Relevance of how MHC class 1 and PD-L1 contribute to tumor cell killing well summarized by this illustration from https://t.co/IklSI1zH9c 🧐 wherein the tumor cell itself becomes the antigen presenting cell 🧐🧐 #pathJC

anueru432's tweet photo. Relevance of how MHC class 1 and PD-L1 contribute to tumor cell killing well summarized by this illustration from https://t.co/IklSI1zH9c 🧐

wherein the tumor cell itself becomes the antigen presenting cell 🧐🧐 #pathJC https://t.co/FJBnNqsZhB

about 5 years ago

#pathjc This study examined MHC class I expression in endometrial carcinomas with mismatch repair and PD-L1 expression - Serous carcinomas were excluded - None of the tumors had previous treatment by chemotherapy, radiotherapy, or immunotherapy

1

3

0

11

4

0

about 5 years ago

#pathjc -Histone deacetylase inhibitors have been studied as a possible intervention to promote protein upregulation in cancers where MHC class I loss is due to epigenetic factor, and show early promise

0

3

0

Pallavi A. Patil, MD @PAPatilMD

about 5 years ago

@PAPatilMD @anueru432 @path_JC It is one of the easier antibodies I have worked up! Not finicky, very clean! #pathJC

1

2

1

0

about 5 years ago

@AnneMillsMD @anueru432 @path_JC #pathjc unfortunately not yet. Will keep you posted :)

1

2

0

about 5 years ago

@anueru432 @path_JC @PAPatilMD do you guys have MHC class I up and running? Interested in your experience with it if so! #pathJC

1

2

1

0

about 5 years ago

@anueru432 @path_JC No, MMRd group deliberately included some Lynch patients as well as patients with MLH1 hypermethylation and somatic mutations. Mechanism of MMRd didn't influence MHC class I expression (in contrast to what we've seen with PD-L1 and TIM-3!). #pathJC

1

2

3

0

about 5 years ago

@path_JC Also big props to 1st author and #UVAPath PGY2 Dr. Lisa Friedman for her beautiful work on this study. She is Twitter-averse but otherwise BRILLIANT! #pathJC

0

3

2

0

about 5 years ago

@path_JC Really enjoyed discussing this study with @DrNetto in a @ModernPathology chat! #pathJC https://t.co/PFnZohjYMr

0

6

5

0

about 5 years ago

#pathJC on to the 2nd article!!